Form Ds provide information on individual, unregistered securities offerings.
Search by Recipient Name or Primary Issuer:
| Recipient | CRD | Primary Issuer | CIK | Filing Date | Form Type | Total Offering Amount | Total Amount Sold |
|---|---|---|---|---|---|---|---|
| CANTOR FITZGERALD & CO. | 134 | CF WAG Portfolio DST | 1931233 | 05/26/2022 | D | $23,140,470 | $23,140,470 |
| CANTOR FITZGERALD & CO. | 134 | Ocuphire Pharma, Inc. | 1228627 | 11/20/2020 | D | $21,150,000 | $21,150,000 |
| CANTOR FITZGERALD & CO. | 134 | CF Chisholm Multifamily DST | 1899445 | 01/07/2022 | D | $55,500,000 | $17,036,467 |
| CANTOR FITZGERALD & CO. | 134 | CF Industry Multifamily DST | 1899423 | 01/07/2022 | D | $42,020,000 | $16,676,461 |
| CANTOR FITZGERALD & CO. | 134 | CF ON3 Lifesciences Parent DST | 1928276 | 05/23/2022 | D | $69,800,000 | $16,293,535 |
| CANTOR FITZGERALD & CO. | 134 | Brooklyn ImmunoTherapeutics, Inc. | 748592 | 03/23/2022 | D | $12,000,000 | $12,000,000 |
| CANTOR FITZGERALD & CO. | 134 | SpringBig Holdings, Inc. | 1801602 | 06/29/2022 | D | $11,000,000 | $11,000,000 |
| CANTOR FITZGERALD & CO. | 134 | CF NET LEASE PORTFOLIO IV DST | 1716556 | 12/21/2021 | D | $21,620,000 | $9,388,132 |
| CANTOR FITZGERALD & CO. | 134 | Aridis Pharmaceuticals, Inc. | 1614067 | 10/26/2020 | D | $8,429,112 | $8,429,112 |
| CANTOR FITZGERALD & CO. | 134 | HTG MOLECULAR DIAGNOSTICS, INC | 1169987 | 03/25/2022 | D | $20,884,736 | $7,499,999 |